We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chicago, IL – November 11, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Accenture plc (ACN - Free Report) , Sanofi (SNY - Free Report) and Dell Technologies Inc. (DELL - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Accenture plc, Sanofi and Dell Technologies Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
Shares of Accenture have underperformed the Zacks Computers - IT Services industry over the past year (-31.2% vs. -18.7%). The company is facing rising competition, which has led to increased talent costs and pricing pressures. Rapid acquisitions have made the company prone to integration risks. The Zacks analyst has a Neutral recommendation on the stock, and would advise a cheaper entry for investors.
Nevertheless, Accenture’s growth strategy focuses on delivering 360-degree value to stakeholders, which is an attractive aspect for the firm. This consulting services provider thrives on the robust demand for application modernization and maintenance, cloud enhancements, and cybersecurity.
Over the years, Accenture has leveraged buyouts to strengthen digital technology and capital project capabilities. Its cash position allows the company to explore different markets. Dividend-seeking investors will find this stock appealing. Also, its liquidity position is a tailwind.
Sanofi’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+2.2% vs. +0.8%). The company beat third-quarter estimates for earnings and sales. Dupixent is a key top-line driver for Sanofi, as it enjoys strong demand across all approved indications and geographies. Sanofi possesses a leading vaccine portfolio.
Several new drugs were launched in the past couple of years that have become significant contributors to Sanofi's accelerated top-line growth profile. Sanofi has increased R&D investments and is achieving significant progress with its pipeline. It has also been active on the M&A front.
However, the generic erosion of Aubagio in all key markets, and lower sales from other mature products are hurting sales. Other headwinds include competitive pressure on influenza vaccines, regular pipeline setbacks and uncertainties from potential U.S. tariffs on EU exports.
Shares of Dell Technologies have outperformed the Zacks Computer - Micro Computers industry over the year-to-date period (+25.2% vs. +8%). The company is benefiting from strong demand for AI servers, driven by ongoing digital transformation and heightened interest in generative AI applications. It secured $8.2 billion in AI server orders, surpassing shipments and building a strong backlog. Strong enterprise demand for AI-optimized servers aids DELL.
A robust partner base that includes NVIDIA, Google and Microsoft has been a major growth driver. However, the company is facing a challenging macroeconomic environment, along with stiff competition in the PC market from companies like HP and Lenovo.
Dell Technologies faces challenges from weaker demand for traditional servers and storage in North America, slower federal spending, and declining consumer PC revenue. Supply-chain costs and competitive pressures in the AI market are also impacting profitability.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Accenture, Sanofi and Dell
For Immediate Releases
Chicago, IL – November 11, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Accenture plc (ACN - Free Report) , Sanofi (SNY - Free Report) and Dell Technologies Inc. (DELL - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Accenture plc, Sanofi and Dell Technologies Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Pre-Markets Up as Government Shutdown Looks to End
Today's Featured Research Reports
Shares of Accenture have underperformed the Zacks Computers - IT Services industry over the past year (-31.2% vs. -18.7%). The company is facing rising competition, which has led to increased talent costs and pricing pressures. Rapid acquisitions have made the company prone to integration risks. The Zacks analyst has a Neutral recommendation on the stock, and would advise a cheaper entry for investors.
Nevertheless, Accenture’s growth strategy focuses on delivering 360-degree value to stakeholders, which is an attractive aspect for the firm. This consulting services provider thrives on the robust demand for application modernization and maintenance, cloud enhancements, and cybersecurity.
Over the years, Accenture has leveraged buyouts to strengthen digital technology and capital project capabilities. Its cash position allows the company to explore different markets. Dividend-seeking investors will find this stock appealing. Also, its liquidity position is a tailwind.
(You can read the full research report on Accenture here >>>)
Sanofi’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+2.2% vs. +0.8%). The company beat third-quarter estimates for earnings and sales. Dupixent is a key top-line driver for Sanofi, as it enjoys strong demand across all approved indications and geographies. Sanofi possesses a leading vaccine portfolio.
Several new drugs were launched in the past couple of years that have become significant contributors to Sanofi's accelerated top-line growth profile. Sanofi has increased R&D investments and is achieving significant progress with its pipeline. It has also been active on the M&A front.
However, the generic erosion of Aubagio in all key markets, and lower sales from other mature products are hurting sales. Other headwinds include competitive pressure on influenza vaccines, regular pipeline setbacks and uncertainties from potential U.S. tariffs on EU exports.
(You can read the full research report on Sanofi here >>>)
Shares of Dell Technologies have outperformed the Zacks Computer - Micro Computers industry over the year-to-date period (+25.2% vs. +8%). The company is benefiting from strong demand for AI servers, driven by ongoing digital transformation and heightened interest in generative AI applications. It secured $8.2 billion in AI server orders, surpassing shipments and building a strong backlog. Strong enterprise demand for AI-optimized servers aids DELL.
A robust partner base that includes NVIDIA, Google and Microsoft has been a major growth driver. However, the company is facing a challenging macroeconomic environment, along with stiff competition in the PC market from companies like HP and Lenovo.
Dell Technologies faces challenges from weaker demand for traditional servers and storage in North America, slower federal spending, and declining consumer PC revenue. Supply-chain costs and competitive pressures in the AI market are also impacting profitability.
(You can read the full research report on Dell Technologies here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.